{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:03:36Z","timestamp":1785402216646,"version":"3.56.0"},"reference-count":28,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander Stiftung","doi-asserted-by":"publisher","award":["2025.172.1"],"award-info":[{"award-number":["2025.172.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2025.172.1"],"award-info":[{"award-number":["2025.172.1"]}],"id":[{"id":"https:\/\/ror.org\/02q83sc19","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Objectives: A high-performance liquid chromatography (HPLC) with mass spectrometry (MS) detection method was developed to quantify several tyrosine kinase inhibitors (TKIs) and their relevant metabolites. This method is suitable for therapeutic drug monitoring (TDM) of alectinib, brigatinib, dabrafenib, lenvatinib, lorlatinib, osimertinib and trametinib in patients with solid tumors using volumetric absorptive microsampling (VAMS\u00ae). Methods: The HPLC-MS system contained four pumps, a Turboflow HTLC CycloneTM 1.0 \u00d7 50 mm solid phase extraction column for analyte enrichment, and a Kinetex 2.6 \u00b5m C18 100\u00c5, 100 \u00d7 3.0 mm column for analyte separation. An acetonitrile\u2013water gradient was used for the separation, and the ions generated by ESI (+)-ionization were detected in single-ion mode. This method was validated according to recent European Medicines Agency (EMA) and Food and Drug Administration (FDA) guidelines. Results: The accuracy and precision shown during method validation were within the acceptable limits for all analytes in plasma and whole blood. All analytes showed acceptable stability in both matrices for at least 28 days when stored at \u221221 \u00b0C. So far, 100 venous plasma and 94 capillary blood samples have been collected and analyzed. Conclusions: We developed a reliable method to quantify several TKIs from plasma and capillary blood, which is intended for TDM purposes in clinical practice.<\/jats:p>","DOI":"10.3390\/pharmaceutics18080923","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:11:56Z","timestamp":1785168716000},"page":"923","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HPLC-MS Quantification of Multiple Tyrosine Kinase Inhibitors in Patients with Solid Tumors: Method Validation and Clinical Application"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6788-5979","authenticated-orcid":false,"given":"Juliane","family":"Staudinger","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Institute of Pharmaceutical and Medicinal Chemistry, University Muenster, 48149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-5297","authenticated-orcid":false,"given":"Marcel","family":"Kemper","sequence":"additional","affiliation":[{"name":"Medical Clinic A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Krekeler","sequence":"additional","affiliation":[{"name":"Medical Clinic A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4651-0615","authenticated-orcid":false,"given":"Lea","family":"Reitnauer","sequence":"additional","affiliation":[{"name":"Medical Clinic A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalen","family":"Bleckmann","sequence":"additional","affiliation":[{"name":"Medical Clinic A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Muenster, 48149 Muenster, Germany"},{"name":"West German Cancer Center, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-6423","authenticated-orcid":false,"given":"Georg","family":"Hempel","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Institute of Pharmaceutical and Medicinal Chemistry, University Muenster, 48149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s40262-023-01293-9","article-title":"Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology","volume":"62","author":"Guchelaar","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2012.43.5362","article-title":"Evidence for therapeutic drug monitoring of targeted anticancer therapies","volume":"30","author":"Gao","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.21873\/anticanres.16211","article-title":"Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients with Non-small Cell Lung Cancer","volume":"43","author":"Yamazaki","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s10637-023-01328-9","article-title":"Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: A Prospective Observational Study","volume":"41","author":"Ishikawa","year":"2023","journal-title":"Investig. New Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jpba.2016.06.037","article-title":"Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology","volume":"130","author":"Rood","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Verougstraete, N., Stove, V., Verstraete, A.G., and Stove, C.P. (2022). Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.821807"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/FTD.0000000000001175","article-title":"Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites","volume":"46","author":"Meertens","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"114418","DOI":"10.1016\/j.jpba.2021.114418","article-title":"Volumetric absorptive microsampling as a suitable tool to monitor tyrosine kinase inhibitors","volume":"207","author":"Verougstraete","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"114623","DOI":"10.1016\/j.jpba.2022.114623","article-title":"Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio","volume":"211","author":"Zimmermann","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"115033","DOI":"10.1016\/j.jpba.2022.115033","article-title":"Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS","volume":"221","author":"Opitz","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_13","unstructured":"European Medicines Agency (2023). ICH Guideline M10 on Bioanalytical Method Validation and Study Sample Analysis_Step 5, European Medicines Agency."},{"key":"ref_14","unstructured":"FDA, and CDER (2018). Bioanalytical Method Validation Guidance for Industry."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.aca.2018.09.004","article-title":"Tutorial: Volumetric absorptive microsampling (VAMS)","volume":"1046","author":"Protti","year":"2019","journal-title":"Anal. Chim. Acta"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/cts.13231","article-title":"Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC","volume":"15","author":"Gupta","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17588359221103212","DOI":"10.1177\/17588359221103212","article-title":"Improving the tolerability of osimertinib by identifying its toxic limit","volume":"14","author":"Agema","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"107954","DOI":"10.1016\/j.lungcan.2024.107954","article-title":"Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification","volume":"196","author":"Igawa","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mc Laughlin, A.M., Schmulenson, E., Teplytska, O., Zimmermann, S., Opitz, P., Groenland, S.L., Huitema, A.D.R., Steeghs, N., M\u00fcller, L., and Fuxius, S. (2021). Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers, 13.","DOI":"10.3390\/cancers13246281"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3892\/ol.2016.4780","article-title":"Therapeutic drug monitoring and tyrosine kinase inhibitors","volume":"12","author":"Herviou","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102064","DOI":"10.1016\/j.clgc.2024.102064","article-title":"Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma","volume":"22","author":"Henriksen","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jchromb.2011.09.041","article-title":"Therapeutic drug monitoring and LC-MS\/MS","volume":"883\u2013884","author":"Adaway","year":"2012","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tuzimski, T., and Petruczynik, A. (2020). Review of Chromatographic Methods Coupled with Modern Detection Techniques Applied in the Therapeutic Drugs Monitoring (TDM). Molecules, 25.","DOI":"10.3390\/molecules25174026"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4155\/bio-2020-0136","article-title":"Validation and clinical application of a volumetric absorptive microsampling method for 14 psychiatric drugs","volume":"12","author":"Stern","year":"2020","journal-title":"Bioanalysis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FTD.0000000000001157","article-title":"A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma","volume":"46","author":"Venkatesh","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"113102","DOI":"10.1016\/j.jpba.2020.113102","article-title":"Opportunities and obstacles for microsampling techniques in bioanalysis: Special focus on DBS and VAMS","volume":"182","author":"Londhe","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/cts.13515","article-title":"Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling","volume":"16","author":"Liu","year":"2023","journal-title":"Clin. Transl. Sci."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/8\/923\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:15:34Z","timestamp":1785168934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/8\/923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["pharmaceutics18080923"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18080923","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}